Addressing Working Capital and Investment Funding Through Internal Funds, Corporate Bonds and Borrowings
First written in FY2017-Q1. 14 of 31 entries say "Restated". Latest entry: FY2026.
21 other companies' latest entry also says "Other".
- FY2026Lower borrowings and increased commitment facilitiesAnnual report
「Capital expenditures during the current consolidated fiscal year are being financed primarily through borrowings, and borrowings outstanding at the end of the fiscal year were ¥39,103 million. In addition, our group has entered into overdraft agreements and loan commitment agreements with 6 relationship banks, securing total credit facilities of ¥35,950 million, of which ¥10,166 million remained unused at the end of the fiscal year.」
While continuing the policy of financing capital expenditures primarily through borrowings, borrowings outstanding decreased from ¥46,227 million in the previous fiscal year to ¥39,103 million, and commitment facilities increased to ¥35,950 million. - FY2026-H1Continued repayment of borrowingsAnnual report
「During the current interim consolidated accounting period, funds decreased by ¥3,350 million, an increase of ¥1,780 million from the same interim period of the previous year. This was mainly due to a ¥419 million decrease in short-term borrowings, ¥1,663 million in repayments of long-term borrowings, and ¥1,055 million in dividend payments.」
Funding activities involving repayment of borrowings progressed, including a ¥419 million decrease in short-term borrowings and ¥1,663 million in repayments of long-term borrowings. - FY2025Lower borrowings and increased commitment facilitiesAnnual report
「Capital expenditures during the current consolidated fiscal year are being financed primarily through borrowings, and borrowings outstanding at the end of the fiscal year were ¥41,164 million. In addition, our group has entered into overdraft agreements and loan commitment agreements with 6 relationship banks, securing total credit facilities of ¥34,450 million, of which ¥9,646 million remained unused at the end of the fiscal year.」
While continuing the policy of financing capital expenditures primarily through borrowings, borrowings outstanding decreased from ¥46,227 million in the previous fiscal year to ¥41,164 million, and commitment facilities increased to ¥34,450 million. - FY2025-H1Decrease in short- and long-term borrowingsAnnual report
「During the current interim consolidated accounting period, funds decreased by ¥5,130 million, a decrease of ¥2,845 million from the same interim period of the previous year. This was mainly due to a ¥928 million decrease in short-term borrowings, ¥1,000 million in proceeds from long-term borrowings, ¥4,039 million in repayments of long-term borrowings, and ¥965 million in dividend payments.」
During the current interim consolidated accounting period, short-term borrowings decreased by ¥928 million and long-term borrowings were repaid by ¥4,039 million, while ¥1,000 million in long-term borrowings was raised. - FY2024Borrowing to finance capital expenditures and decrease in long-term borrowingsAnnual report
「Capital expenditures during the current consolidated fiscal year are being financed primarily through borrowings, and borrowings outstanding at the end of the fiscal year were ¥46,227 million. In addition, our group has entered into overdraft agreements and loan commitment agreements with 6 relationship banks, securing total credit facilities of ¥33,450 million, of which ¥10,225 million remained unused at the end of the fiscal year.」
Capital expenditures were financed primarily through borrowings, with borrowings outstanding of ¥46,227 million and commitment facilities of ¥33,450 million with 6 relationship banks. - FY2024-Q2Continued increase in short-term borrowings and repayment of long-term borrowingsAnnual report
「During the current six-month consolidated period, funds decreased by ¥2,285 million, a decrease of ¥166 million from the same period of the previous year. This was mainly due to an ¥1,168 million increase in short-term borrowings, ¥500 million in proceeds from long-term borrowings, ¥2,824 million in repayments of long-term borrowings, and ¥966 million in dividend payments.」
Continuing to combine borrowing and repayment activities, including increases in short-term borrowings, new long-term borrowings and repayments of long-term borrowings. - FY2024-Q1Change in Borrowing MixAnnual report
「Total liabilities at the end of the current three-month consolidated accounting period were ¥71,740 million, an increase of ¥2,386 million from the end of the previous consolidated fiscal year. The main changes in current liabilities were a ¥989 million increase in accounts payable and a ¥3,695 million increase in short-term borrowings. The main change in non-current liabilities was a ¥2,482 million decrease in long-term borrowings.」
Short-term borrowings increased by ¥3,695 million while long-term borrowings decreased by ¥2,482 million at the end of the current first quarter, indicating a change in the borrowing structure. - FY2023AdvancedAnnual report
「Capital expenditures during the current consolidated fiscal year are being financed through internal funds and borrowings, and borrowings outstanding at the end of the fiscal year were ¥49,431 million. In addition, our group has entered into overdraft agreements and loan commitment agreements with 7 relationship banks, securing total credit facilities of ¥32,450 million, of which ¥10,288 million remained unused at the end of the fiscal year.」
Capital expenditures were financed through internal funds and borrowings, with borrowings outstanding of ¥49,431 million and total commitment facilities of ¥32,450 million with 7 banks. - FY2023-Q3RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and short- and long-term borrowings.」
Continuing the policy of meeting funding needs such as working capital and capital expenditures through internal funds, bonds, and long- and short-term borrowings. - FY2023-Q2RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and short- and long-term borrowings.」
Continuing the policy of meeting funding needs such as working capital and capital expenditures through internal funds, bonds, and long- and short-term borrowings. - FY2023-Q1RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and short- and long-term borrowings.」
Continuing the policy of meeting funding needs such as working capital and capital expenditures through internal funds, bonds, and long- and short-term borrowings. - FY2022-Q3RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and short- and long-term borrowings.」
Continuing the policy of meeting funding needs such as working capital and capital expenditures through internal funds, bonds, and long- and short-term borrowings. - FY2022-Q2RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and short- and long-term borrowings.」
Continuing the policy of meeting funding needs such as working capital and capital expenditures through internal funds, bonds, and long- and short-term borrowings. - FY2022-Q1RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and short- and long-term borrowings.」
Continuing the policy of meeting funding needs such as working capital and capital expenditures through internal funds, bonds, and long- and short-term borrowings. - FY2021-Q3AdvancedAnnual report
「During the current nine-month consolidated period, interest-bearing liabilities, including long- and short-term borrowings, increased by ¥16,496 million because the acquisition of shares in 日水製薬医薬品販売株式会社 and the transfer to Tillotts Pharma AG, the Swiss subsidiary, of the marketing authorizations for Dificlir tablets in Europe, the Middle East, Africa and the Commonwealth of Independent States were financed primarily through borrowings by the company.」
The acquisition of shares in 日水製薬医薬品販売 and the transfer of the manufacturing and marketing rights for Dificlir tablets were financed primarily through borrowings, increasing interest-bearing liabilities by ¥16,496 million. - FY2021-Q2RestatedAnnual report
「During the current six-month consolidated period, interest-bearing liabilities, including long- and short-term borrowings, increased by ¥4,539 million because the acquisition of shares in 日水製薬医薬品販売株式会社 and other items was financed primarily through borrowings.」
It explains that the acquisition of shares in 日水製薬医薬品販売 and other items was financed primarily through borrowings, resulting in a ¥4,539 million increase in interest-bearing liabilities. - FY2021-Q1AdvancedAnnual report
「During the current three-month consolidated period, interest-bearing liabilities, including long- and short-term borrowings, increased by ¥4,526 million because the acquisition of shares in 日水製薬医薬品販売株式会社 and other items was financed primarily through borrowings.」
The acquisition of shares in 日水製薬医薬品販売 and other items was financed primarily through borrowings, increasing interest-bearing liabilities by ¥4,526 million. - FY2020RestatedAnnual report
「Capital expenditures during the current consolidated fiscal year are being financed primarily through borrowings, and borrowings outstanding at the end of the fiscal year were ¥35,175 million. In addition, our group has entered into overdraft agreements and loan commitment agreements with 7 relationship banks, securing total credit facilities of ¥31,450 million, of which ¥12,546 million remained unused at the end of the fiscal year.」
Financing capital expenditures primarily through borrowings and maintaining total commitment facilities of ¥31,450 million with 7 banks. - FY2020-Q3RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and long- and short-term borrowings. During the current nine-month consolidated period, we updated factory equipment and existing systems and other items, primarily using internal funds.」
Continuing the policy of meeting needs such as working capital and capital expenditures through internal funds, bonds, and long- and short-term borrowings, while financing factory equipment and existing-system upgrades primarily through internal funds. - FY2020-Q2RestatedAnnual report
「During the current six-month consolidated period, we updated factory equipment and existing systems and other items, primarily using internal funds.」
Factory equipment and existing systems were updated, while the policy of financing these needs primarily through internal funds continued. - FY2020-Q1AdvancedAnnual report
「During the current three-month consolidated period, we updated existing systems and other items, primarily using internal funds.」
Existing systems and other items were updated, with the funding provided primarily through internal funds. - FY2019ReframedAnnual report
「Capital expenditures during the current consolidated fiscal year are being financed primarily through borrowings. We plan to replace aging factory equipment and other items during this period, using internal funds and long- and short-term borrowings.」
Regarding funding needs, capital expenditures for the current fiscal year were described as being financed primarily through borrowings, indicating a shift in emphasis from the previous practice of relying primarily on internal funds. - FY2019-Q3RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and long- and short-term borrowings. During the current nine-month consolidated period, we replaced aging factory equipment and other items, primarily using internal funds.」
Continuing the policy of meeting needs such as working capital and capital expenditures through internal funds, bonds, and long- and short-term borrowings, while replacing factory equipment primarily with internal funds. - FY2019-Q2RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and long- and short-term borrowings. During the current six-month consolidated period, we replaced aging factory equipment and other items, primarily using internal funds.」
Continuing the policy of meeting needs such as working capital and capital expenditures through internal funds, bonds, and short- and long-term borrowings, while replacing factory equipment during the quarter primarily with internal funds. - FY2019-Q1AdvancedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and long- and short-term borrowings. During the current three-month consolidated period, we replaced aging factory equipment and other items, primarily using internal funds.」
While continuing to use these funding methods to meet funding needs, we replaced aging factory equipment and other items during the quarter, primarily using internal funds. - FY2018AdvancedAnnual report
「During this period, we plan to update our core systems and replace aging factory equipment, and intend to finance these needs through internal funds and long- and short-term borrowings.」
It presents a plan to meet new funding needs for core-system upgrades and factory equipment replacement through internal funds and long- and short-term borrowings. - FY2018-Q2AdvancedAnnual report
「During the current six-month consolidated period, funds decreased by ¥3,001 million, a decrease of ¥481 million from the same period of the previous year. This was mainly due to a ¥6,523 million decrease in short-term borrowings, ¥9,868 million in proceeds from long-term borrowings, ¥1,159 million in repayments of long-term borrowings, ¥4,331 million in payments for the acquisition of treasury shares, and ¥847 million in dividend payments.」
During the current six-month period, a decrease in short-term borrowings, new long-term borrowings, repayment of borrowings, treasury share purchases and dividend payments occurred as specific cash flows. - FY2017AdvancedAnnual report
「Capital expenditure during the current consolidated fiscal year and additional investment in Pharmaceutical Joint Stock Company of February 3rd were financed primarily through internal funds.」
It describes the specific results of primarily using internal funds during the current fiscal year to finance capital expenditures and additional investment in the Vietnamese subsidiary. - FY2017-Q3RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and short- and long-term borrowings.」
Continuing the policy of meeting funding needs such as working capital and capital expenditures through internal funds, bonds, and long- and short-term borrowings. - FY2017-Q2RestatedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and short- and long-term borrowings.」
Continuing the policy of meeting funding needs such as working capital and capital expenditures through internal funds, bonds, and long- and short-term borrowings. - FY2017-Q1First statedAnnual report
「Our group meets these funding needs through internal funds, bond issuance, and short- and long-term borrowings.」
For funding needs such as working capital and capital expenditures, internal funds, bonds, and long- and short-term borrowings were first identified as financing methods under this theme.